FLT1: Difference between revisions
m (Bot: Automated text replacement (-{{SIB}} + & -{{EJ}} + & -{{EH}} + & -{{Editor Join}} + & -{{Editor Help}} +)) |
m (Robot: Automated text replacement (-{{WikiDoc Cardiology Network Infobox}} +, -<references /> +{{reflist|2}}, -{{reflist}} +{{reflist|2}})) |
||
Line 15: | Line 15: | ||
==References== | ==References== | ||
{{reflist}} | {{reflist|2}} | ||
==Further reading== | ==Further reading== |
Latest revision as of 17:19, 4 September 2012
WikiDoc Resources for FLT1 |
Articles |
---|
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on FLT1 at Clinical Trials.gov Clinical Trials on FLT1 at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on FLT1
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Directions to Hospitals Treating FLT1 Risk calculators and risk factors for FLT1
|
Healthcare Provider Resources |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascular permeability factor receptor), also known as FLT1, is a human gene.
Oncogene FLT belongs to the src gene family and is related to oncogene ROS (MIM 165020). Like other members of this family, it shows tyrosine protein kinase activity that is important for the control of cell proliferation and differentiation. The sequence structure of the FLT gene resembles that of the FMS gene (MIM 164770); hence, Yoshida et al. (1987) proposed the name FLT as an acronym for FMS-like tyrosine kinase.[supplied by OMIM][1]
See also
References
Further reading
- Petrova TV, Makinen T, Alitalo K (1999). "Signaling via vascular endothelial growth factor receptors". Exp. Cell Res. 253 (1): 117–30. doi:10.1006/excr.1999.4707. PMID 10579917.
- Sato Y, Kanno S, Oda N; et al. (2000). "Properties of two VEGF receptors, Flt-1 and KDR, in signal transduction". Ann. N. Y. Acad. Sci. 902: 201–5, discussion 205–7. PMID 10865839.
- Boyd AW, Lackmann M (2002). "Signals from Eph and ephrin proteins: a developmental tool kit". Sci. STKE. 2001 (112): RE20. doi:10.1126/stke.2001.112.re20. PMID 11741094.
- Luttun A, Tjwa M, Carmeliet P (2003). "Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders". Ann. N. Y. Acad. Sci. 979: 80–93. PMID 12543719.
- Maynard SE, Venkatesha S, Thadhani R, Karumanchi SA (2005). "Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia". Pediatr. Res. 57 (5 Pt 2): 1R–7R. doi:10.1203/01.PDR.0000159567.85157.B7. PMID 15817508.
- Shibuya M (2007). "Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis". Angiogenesis. 9 (4): 225–30, discussion 231. doi:10.1007/s10456-006-9055-8. PMID 17109193.
- Widmer M, Villar J, Benigni A; et al. (2007). "Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review". Obstetrics and gynecology. 109 (1): 168–80. doi:10.1097/01.AOG.0000249609.04831.7c. PMID 17197602.
- López-Novoa JM (2007). "Soluble endoglin is an accurate predictor and a pathogenic molecule in pre-eclampsia". Nephrol. Dial. Transplant. 22 (3): 712–4. doi:10.1093/ndt/gfl768. PMID 17210583.